This is a regulatory disclosure filed by Akums Drugs and Pharmaceuticals Limited with the National Stock Exchange of India Ltd. and BSE Limited, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The document intimates the cessation of Mr. Sunil Jaiswal from his position as Senior Vice President – Research & Development, a role in which he was also designated as Senior Management Personnel of the Company. The reason for his cessation is resignation due to family commitments. Mr. Jaiswal is 61 years old.
Key Dates and Actions
- Resignation Submission Date: Mr. Jaiswal submitted his resignation on August 5, 2026.
- Requested Relieving Date: In his resignation letter, he requested to be relieved from his duties effective October 30, 2026.
- Agreed Relieving Date: Following discussions, October 31, 2026, was agreed upon as his final relieving date.
Annexure-A Details
The annexure provides the following specifics as mandated by the SEBI Master Circular:
| Particulars | Details |
| 1. Nature of Change | Resignation of Mr. Sunil Jaiswal, Senior Vice President - Research & Development, designated as Senior Management Personnel. |
| 2. Date of Cessation | October 31, 2026 |
| 3. Brief Profile (if appointment) | Not Applicable |
| 4. Disclosure of relationships between directors | Not Applicable |
Resignation Letter Content (Annexure-B)
A copy of the resignation letter dated August 5, 2026, is enclosed. It is addressed to Shri Sandeep Jain, the Managing Director. The letter formally notifies the company of his resignation from the post of Senior Vice President, R&D. Mr. Jaiswal expresses gratitude for the support and opportunities provided and offers assistance for a smooth transition of his duties.
Company Officials
The disclosure is signed by Dharamvir Malik, Company Secretary & Compliance Officer, for Akums Drugs and Pharmaceuticals Limited.
Financial Impact
No financial impact or operational disruption is quantified or mentioned in the disclosure.